GLP1R and type 2 diabetes mellitus: Our findings, therefore, confirm that EQW can be used as treatment for type 2 diabetes without regard to race, but call into question the suggestion of a race-specific cardiometabolic contribution to the lower incidence of MACE in Asian participants, as suggested by the meta-analysis of data from GLP-1 RA cardiovascular outcome trials including Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [LEADER], Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes [SUSTAIN-6], and EXSCEL [3, 5].